JNCI Cancer Spectrum最新文献

{"title":"Targeted therapy use following Medicare's coverage expansion for next-generation sequencing in older adults with lung cancer.","authors":"So-Yeon Kang, Patrick C Roney, Jaeil Ahn, Tania Lobo, Carole Roan Gresenz, Arnold L Potosky, Anita Y Kinney, Marc D Schwartz","doi":"10.1093/jncics/pkag113","DOIUrl":"https://doi.org/10.1093/jncics/pkag113","url":null,"abstract":"<p><strong>Purpose: </strong>To examine whether Medicare's 2018 National Coverage Determination (NCD) for next-generation sequencing (NGS) was associated with changes in the use of targeted oral anticancer therapies among older adults with lung cancer.</p><p><strong>Methods: </strong>Retrospective cohort study. Multivariable logistic regression was used to estimate the probability of initiating an oral targeted therapy within 12 months of diagnosis. Key exposures were (1) diagnosis before versus after the NCD and (2) residence in a region with versus without pre-NCD NGS. Data were drawn from the SEER-Medicare linked data with Part D claims, including diagnosis years 2016-2019 with follow-up through 2020. The analytic sample included Medicare fee-for-service Part D beneficiaries aged 65 years or older with newly diagnosed lung cancer.</p><p><strong>Results: </strong>Among 30,855 Medicare fee-for-service Part D beneficiaries with lung cancer, 7.1% used targeted oral anticancer therapies. The NCD was not associated with a significant overall change in targeted therapy use (0.4 Percentage Point; 95% CI, -1.6 to 2.4; p = 0.71). Before NCD implementation, targeted therapy use was 1.0 PP higher in regions with pre-NCD NGS coverage than in regions without such coverage (95% CI, 0.2-1.9; p = 0.015). In stage-stratified analyses, the additional post-NCD change was significant among patients with distant-stage disease (3.2 PPs; 95% CI, 2.6-4.0; p < 0.001) but not among those with regional-stage disease (p = 0.29).</p><p><strong>Conclusions: </strong>Medicare's NCD for NGS was not associated with a significant overall increase in targeted oral anticancer therapy use but was associated with increased use among patients with distant-stage disease. Targeted therapy use remained higher in regions with preexisting NGS coverage.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149231066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Flavonoids and survival in stage III colon cancer: CALGB/SWOG 80702 (alliance).","authors":"Seohyuk Lee, Chao Ma, Qian Shi, Pankaj Kumar, Felix Couture, Philip Kuebler, Smitha Krishnamurthi, Benjamin Tan, Ardaman Shergill, Eileen M O'Reilly, Anthony F Shields, Jeffrey A Meyerhardt","doi":"10.1093/jncics/pkag112","DOIUrl":"https://doi.org/10.1093/jncics/pkag112","url":null,"abstract":"<p><strong>Introduction: </strong>We sought to evaluate the associations of post-diagnostic consumption of flavonoids and flavonoid-rich foods with survival among patients with stage III colon cancer enrolled in a clinical trial.</p><p><strong>Methods: </strong>We conducted a prospective observational study of 1625 patients with stage III colon cancer enrolled in the CALGB/SWOG 80702 (Alliance) randomized adjuvant chemotherapy trial who completed a self-reported food frequency questionnaire within 6 weeks of and again 14-16 months post-randomization. Intakes of flavonoids overall and by subclasses (anthocyanidins, flavanones, flavan-3-ols, flavones, flavonols, isoflavones) were computed by multiplying the consumption frequency of each dietary item by the nutrient content of its respective specified portions. Multivariable analyses for the primary (disease-free survival [DFS]) and secondary (overall survival [OS]) endpoints were adjusted for sociodemographic, clinical, dietary, and lifestyle factors. Bonferroni corrections were applied for analyses of flavonoid subclasses and flavonoid-rich foods.</p><p><strong>Results: </strong>Over median follow-up of 5.9 years, flavonoid consumption either overall or by subclasses was not significantly associated with survival outcomes, with a hazard ratio (HR) (95% confidence interval [CI]) of 1.01 (0.75-1.37) for DFS among those in the highest relative to lowest consumption quintiles of total flavonoids. Exploratory analyses of flavonoid-rich foods intake did not demonstrate significant associations with DFS or OS after Bonferroni correction.</p><p><strong>Conclusion: </strong>Among resected stage III colon cancer patients who received standardized treatment and follow-up within a nationwide randomized clinical trial, consumption of flavonoids was not associated with survival outcomes.ClinicalTrials.gov identifier: NCT01150045.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149231104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When Actionable Genomic Findings Do Not Translate into Treatment in Precision Oncology.","authors":"Ewan K Cobran","doi":"10.1093/jncics/pkag115","DOIUrl":"https://doi.org/10.1093/jncics/pkag115","url":null,"abstract":"<p><p>Comprehensive genomic profiling has expanded the ability to identify potentially actionable molecular alterations across cancers, but identification of an actionable finding does not ensure that a patient will receive a genomically matched therapy. Studies of precision-oncology programs and molecular tumor boards consistently demonstrate substantial attrition between treatment recommendation and treatment initiation. The reasons extend beyond molecular interpretation and include the timing of genomic profiling, clinical deterioration, geographic availability of biomarker-selected trials, insurance and financial barriers, and disparities in access to specialty cancer care. Importantly, these barriers arise after a potentially useful molecular finding has already been identified, creating a distinction between molecular actionability and practical treatment access. This commentary argues that the next implementation challenge for precision oncology is to make clinically meaningful genomic findings realistically actionable. Comprehensive genomic profiling should occur early enough to inform treatment planning; molecular tumor board recommendations should be linked to realistic treatment and trial opportunities; financial and insurance barriers should be anticipated when recommendations are made; and equity should be evaluated beyond access to testing to include receipt of genomically informed treatment. As genomic profiling becomes increasingly integrated into routine cancer care, precision oncology should be judged not only by its ability to identify therapeutic opportunities but also by whether patients can reach those opportunities while they remain clinically relevant.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149193782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival over two decades in neuroendocrine neoplasms care.","authors":"Julie Hallet, Léamarie Meloche-Dumas, Carlotta Sarzo, Jessica Armah, Anna Ding, Wing Chan, Simron Singh","doi":"10.1093/jncics/pkag111","DOIUrl":"https://doi.org/10.1093/jncics/pkag111","url":null,"abstract":"<p><strong>Background: </strong>The incidence of gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) has increased, alongside novel therapies and care models. Whether these advances translated into improved survival is unclear.</p><p><strong>Methods: </strong>Population-based retrospective cohort study of GEP-NENs between 2000-2019. Overall survival (OS) was analyzed using time-to-event methods. Restricted cubic splines assessed non-linear associations between diagnosis year and hazards of death; multivariable Cox regression adjusted for age, sex, primary site, and metastatic status.</p><p><strong>Results: </strong>Among 9,420 patients, 5-year OS was 75.8% overall, 88.8% for non-metastatic disease, and 57.0% for metastatic disease. Mortality risk declined in more recent years, with diagnoses in 2013-2019 associated with lower hazards of death (adjusted HR 0.91, 95%CI 0.83-0.99). Improvements were confined to non-metastatic disease and to pancreas, stomach, and rectal primaries.</p><p><strong>Conclusion: </strong>OS has modestly improved over two decades, largely reflecting stage migration rather than clear therapeutic gains. Advances that meaningfully improve survival in advanced GEP-NENs are needed.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 and thrombotic risk in patients with active cancer: a matched cohort study.","authors":"Jérôme Doyen, Alexandre Lacour, Renaud Schiappa, Eva Seutin, Amanda Garrido, Tanguy Pace Loscos, Denis Doyen","doi":"10.1093/jncics/pkag110","DOIUrl":"https://doi.org/10.1093/jncics/pkag110","url":null,"abstract":"<p><p>COVID-19 has been associated with an increased thrombotic risk, potentially exacerbated in patients with active cancer. We conducted a retrospective cohort study including 119 cancer patients with COVID-19 and 214 matched pre-pandemic controls. Patients with COVID-19 had poorer performance status and were more frequently treated with palliative intent. After a median follow-up of 32.7 months, overall thrombotic event rates did not differ between groups. However, after adjustment for clinically relevant covariates and accounting for death as a competing event, COVID-19 status and palliative treatment intent remained independently associated with a higher cumulative incidence of thrombotic events. In conclusion, COVID-19 may increase thrombotic risk in patients with cancer and occurs more frequently in patients with poorer clinical status. These findings are exploratory and require confirmation in larger prospective studies.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149166660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Historical redlining and breast cancer screening in a regional spatial analysis.","authors":"Derrick Asante, Atikur Rahman, Isuru Ratnayake, Sam Pepper, Ananda Jayawardhana, Leah Lambart, Susan Beckman, Hope Krebill, Ronald Chen, Dinesh Pal Mudaranthakam","doi":"10.1093/jncics/pkag109","DOIUrl":"https://doi.org/10.1093/jncics/pkag109","url":null,"abstract":"<p><strong>Background: </strong>Redlining, introduced in 1933 by the Homeowners' Loan Corporation, created enduring structural inequities in housing, health care access, and neighborhood investment. These historical patterns may contribute to persistent disparities in breast cancer screening. This study examines how historical redlining, alongside contemporary socioeconomic factors, shapes screening disparities across the University of Kansas Cancer Center (KUCC) catchment area.</p><p><strong>Methods: </strong>We conducted a census tract-level spatial analysis across 123 counties (Kansas and western Missouri) by linking CDC PLACES breast cancer screening data with historical redlining maps. Explanatory variables included rurality, mammography facility availability, income inequality, gender pay gap, and uninsured rates. Logistic regression assessed overall associations, while geographically weighted binomial logistic regression evaluated spatial heterogeneity.</p><p><strong>Results: </strong>Screening rates ranged from 56.9% to 84.5% across census tracts. Redlining was associated with lower screening odds in unadjusted models but was attenuated after accounting for socioeconomic and geographic factors. Rurality and income inequality were consistently associated with lower screening, whereas greater mammography facility availability was associated with higher screening rates. Spatial analyses revealed meaningful geographic variation, with localized negative associations of redlining and persistent, spatially varying effects of socioeconomic factors.</p><p><strong>Conclusion: </strong>Breast cancer screening disparities in this region reflect the combined influence of historical structural inequities and current socioeconomic conditions. Expanding access to mammography and implementing spatially targeted, equity-focused interventions may improve screening uptake and reduce disparities in underserved communities.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149169412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Provider Communication About Colorectal Cancer Screening Tests Among U.S. Adults.","authors":"Chinenye Lynette Ejezie, Chengcheng Zhang","doi":"10.1093/jncics/pkag106","DOIUrl":"https://doi.org/10.1093/jncics/pkag106","url":null,"abstract":"<p><p>This cross-sectional study examined patient-provider communication about colorectal cancer screening options using the 2024 Health Information National Trends Survey. The outcome measure was respondents' report of being informed by a health care professional about multiple colorectal cancer screening tests. Covariates included race/ethnicity, income, education, number of health care visits, insurance, age, and sex. Uninsured participants had lower odds (adjusted OR, 0.65; 95% CI, 0.46-0.93) of reporting colorectal cancer screening discussions than insured participants. Those who earned <$20,000 had lower odds (adjusted OR, 0.58; 95% CI, 0.41-0.81) of reporting colorectal cancer screening discussions than those earning ≥$100,000. The predicted probability of a health care provider visit was lowest among respondents with no health care visits (adjusted probability, 33.3%; 95% CI, 25.3-41.2), compared with those in the other health care visit categories. Differences in colorectal cancer screening discussions were observed across groups. Further research should identify contributing factors.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149169754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma metabolomic profiles associated with breastfeeding history and subsequent ovarian cancer risk.","authors":"Jennifer M Mongiovi, Nicole Prince, Julian Avila Pacheco, Nan Lin, Mary K Townsend, Britton Trabert, Nicolas Wentzensen, Jessica A Lasky-Su, A Heather Eliassen, Clary B Clish, Shelley S Tworoger, Oana A Zeleznik, Naoko Sasamoto","doi":"10.1093/jncics/pkag108","DOIUrl":"https://doi.org/10.1093/jncics/pkag108","url":null,"abstract":"<p><strong>Background: </strong>Breastfeeding reduces ovarian cancer risk, but the underlying biological mechanisms remain unclear.</p><p><strong>Methods: </strong>We examined the association between a previously reported metabolite-based breastfeeding score with incident epithelial ovarian cancer risk in case-control studies nested within the Nurses' Health Studies (NHS/NHSII, n = 436) and Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO, n = 300) using conditional logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for each study and conducted a meta-analysis. We investigated 606 individual breastfeeding-metabolite associations among 9,904 mid-life parous women in NHS/NHSII and 663 one-year postpartum women in the Vitamin D Antenatal Asthma Reduction Trial (VDAART). Metabolites associated with breastfeeding at p ≤ 0.05 after multiple testing correction for number of effective tests (NEF) were then assessed for their associations with ovarian cancer. Metabolite set enrichment analysis using Normalized Enrichment Score (NES) identified metabolite classes associated with breastfeeding using false discovery rate (FDR) were used for multiple testing correction.</p><p><strong>Results: </strong>The highest quartile of metabolite-based breastfeeding score was inversely associated with ovarian cancer risk (meta-analyzed odds ratio [OR]=0.62, 95%CI=0.39-0.99). Of the 14 individual metabolites associated with breastfeeding in NHS/NHSII and also measured in VDAART, similar direction of associations was observed for 11 metabolites. Phosphatidylcholines (PCs; NES=1.94; FDR=0.004) and phosphatidylethanolamines (PEs; NES=1.82; FDR=0.01) were positively enriched with increased breastfeeding duration. Ten metabolites including PCs and PEs were positively associated with breastfeeding and inversely associated with ovarian cancer.</p><p><strong>Conclusion(s): </strong>Our results suggest alterations of systemic metabolism, particularly among PC and PE pathways, provide insight into biological pathways underlying the inverse breastfeeding-ovarian cancer association.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149169416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Population‑based registry analysis of cervical cancer trends in Tashkent Uzbekistan 2014-2024.","authors":"Ulugbek Khudayberdievich Mirzaev, Jasur Ravshanovich Juraev, Iroda Pulatovna Sharipova, Sarvar Temurovich Islomov, Nodira Isroilovna Tursunova, Sitora Rakhmatova, Fatima Shokir Qizi Shodieva, Mirzarakhim Mirzakhakimovich Baynazarov, Khasanjon Kobiljon Ugli Odilov, Dilbar Yuldashevna Yuldasheva, Golib Abdulloyevich Khakimov","doi":"10.1093/jncics/pkag107","DOIUrl":"https://doi.org/10.1093/jncics/pkag107","url":null,"abstract":"<p><strong>Introduction: </strong>Cervical cancer remains a leading cause of morbidity and mortality among women in Uzbekistan, exceeding WHO elimination targets. Despite a school-based HPV vaccination program launched in 2019, screening coverage remains low, leading to delayed diagnoses; we examined cervical cancer trends in Tashkent (2014-2024) to evaluate the impact of the Korea Foundation for International Healthcare (KOFIH) screening project and UNFPA/UNDP HPV testing initiatives.</p><p><strong>Methods: </strong>We analyzed Tashkent City Oncoregister data for women diagnosed with invasive cervical cancer or carcinoma in situ (CIS) between 2014 and 2024 (n = 2,140) after data cleaning. We calculated age-standardized incidence and mortality rates, assessed survival using Kaplan-Meier methods, and identified mortality predictors using Cox regression models.</p><p><strong>Results: </strong>The age-standardized incidence of invasive cervical cancer was 14.9 per 100,000. After KOFIH and UNFPA/UNDP implementation, CIS diagnoses increased 3.4-fold (0.2 to 4.7 per 100,000), while the proportion of advanced-stage (III-IV) disease declined by 43%. Five-year survival showed clear stage dependence, ranging from 91.5% for CIS to 27.8% for stage IV. Age and stage were independent predictors of mortality. Crude mortality declined from 10.2 to 1.1 per 100,000 from 2014 to 2024, and case fatality decreased from 48.6% (2014-2019) to 27.2% (2020-2024).</p><p><strong>Conclusion: </strong>Organized screening through KOFIH and UNFPA initiatives can improve early detection and reduce mortality. However, 76.6% of staged invasive cases remain advanced (II-IV), and more than 80% of women have never been screened, underscoring the need to expand screening, sustain HPV vaccination, and strengthen prevention programs in Central Asia.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149136663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Swedish matched-cohort on the association between maternal polyendocrine metabolic ovarian syndrome and next-generation cancer-risk.","authors":"Romina Fornes, Unnur Gudnadottir, Sheila Orwa, Michael Saerens, Elisabet Stener-Victorin, Nele Brusselaers","doi":"10.1093/jncics/pkag104","DOIUrl":"https://doi.org/10.1093/jncics/pkag104","url":null,"abstract":"<p><strong>Background: </strong>Polyendocrine metabolic ovarian syndrome (PMOS) is an endocrine and metabolic disorder associated with adverse perinatal and long-term health outcomes, yet its impact on cancer risk in children remains unclear.</p><p><strong>Methods: </strong>We conducted a nationwide, register-based matched cohort study in Sweden, including children of primiparous women with (N = 22,955) and without PMOS (N = 103,613) born between 1973 and 2018. Children were followed from birth until cancer diagnosis, death, or December 2018. Conditional Cox proportional hazards models estimated the adjusted hazard ratio (aHR) with 95% confidence interval (CI), incorporating time-varying effects when the proportional hazards assumption was violated.</p><p><strong>Results: </strong>During follow-up, 666 children were diagnosed with cancer. Compared with children born to women without PMOS, overall cancer risk among children of women with PMOS differed by sex and over time. Among sons, higher hazards at 1 year were observed (aHR 4.17; 95% CI: 2.51-6.93), decreasing by 10 years (aHR 1.53; 95% CI 1.08-2.18). In daughters, hazard ratios did not indicate a change in overall cancer risk compared to reference. When both sexes were combined, risk of lymphatic and hematopoietic malignancies was higher (aHR 2.43; 95% CI 1.36-4.33). Competing risks of death did not materially alter the associations.</p><p><strong>Conclusions: </strong>Overall cancer risk among children born to women with PMOS differed by sex and over time, with higher risks in sons during early life. These findings suggest that maternal PMOS may be associated with differential cancer susceptibility across the life course.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149109722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}